FDA Launches One-Day Inspectional Assessments to strengthen and expand oversight
FDA is piloting “one-day inspectional assessments” (launched in April 2026) as shorter, focused screening visits that complement—rather than replace—standard FDA inspections.
The intent is to target inspection resources more efficiently, expand surveillance coverage (assess more facilities), generate timelier feedback for lower-risk establishments with less disruption, and improve FDA risk models using data such as recurring compliance themes, facility risk scores, and mismatches between registered and actual operations.
As of late April 2026, FDA reported ~46 assessments completed, with most resulting in No Action Indicated (NAI); assessments can extend beyond one day if significant issues are observed. The pilot runs through FY2026 and FDA is developing metrics (e.g., duration, escalation rates, usefulness for risk-based decisions) to evaluate effectiveness.
Scope (what’s included / not included)
- Included program areas: Multiple FDA inspectorates—human foods, animal foods, biologics, medical products, and clinical research.
- Facility selection: Risk-based criteria (e.g., product type, prior inspection outcomes, operational characteristics).
- Authorities during assessment: Investigators can expand scope or duration if warranted.
- Not a replacement / no policy change: Explicitly does not replace standard inspections and does not change enforcement policy.
- Exclusions/limits: Not intended for higher-risk or more complex facilities that require comprehensive inspection coverage.